Sol-Gel Technologies (SLGL) Assets (2016 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Assets of $58.6 million for Q1 2026, up 116.35% year-over-year from $27.1 million in Q1 2025, and up 95.71% quarter-over-quarter from $29.9 million in Q4 2025.
Sol-Gel Technologies (SLGL) Assets (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Assets for 11 consecutive years, with $58.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 116.35% year-over-year to $58.6 million; the TTM figure through Mar 2026 stood at $58.6 million (up 116.35% YoY), while the FY2025 annual figure was $29.9 million, down 16.54% from the prior year.
- Assets rose to $58.6 million in Q1 2026 per SLGL's latest filing, from $29.9 million in the prior quarter.
- Across five years, Assets topped out at $58.6 million in Q1 2026 and bottomed at $27.1 million in Q1 2025.
- Historically, Assets has averaged $44.6 million across 5 years, with a median of $45.3 million in 2023.
- Annual changes were most pronounced in 2022 — Assets slumped 32.61% — and 2026, when it jumped 116.35%.
- Sol-Gel Technologies' Assets stood at $46.6 million in 2022, then decreased by 2.88% to $45.3 million in 2023, then declined by 20.85% to $35.8 million in 2024, then retreated by 16.54% to $29.9 million in 2025, then jumped by 95.71% to $58.6 million in 2026.
- Business Quant data shows SLGL's Assets at $58.6 million in Q1 2026, $29.9 million in Q4 2025, and $34.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 58.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.55 Mn |
| Dec 31, 2025 | 29.92 Mn |
| Sep 30, 2025 | 34.59 Mn |
| Jun 30, 2025 | 39.31 Mn |
| Mar 31, 2025 | 27.06 Mn |
| Dec 31, 2024 | 35.85 Mn |
| Sep 30, 2024 | 42.98 Mn |
| Jun 30, 2024 | 42.01 Mn |
| Mar 31, 2024 | 39.91 Mn |
| Dec 31, 2023 | 45.29 Mn |
| Sep 30, 2023 | 49.86 Mn |
| Jun 30, 2023 | 55.10 Mn |
| Mar 31, 2023 | 49.04 Mn |
| Dec 31, 2022 | 46.63 Mn |
| Sep 30, 2022 | 51.29 Mn |
| Jun 30, 2022 | 54.98 Mn |
| Mar 31, 2022 | 56.06 Mn |
| Dec 31, 2021 | 69.19 Mn |
| Sep 30, 2021 | 52.83 Mn |
| Jun 30, 2021 | 46.41 Mn |